Verve Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Verve Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: VERV
TL;DR
**VERVE THERAPEUTICS (VERV) Q1 2025 10-Q FILED - FINANCIALS UPDATED**
AI Summary
Verve Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's business address is 201 Brookline Avenue, Suite 601, Boston, MA 02215. Key financial data points include retained earnings and details on various investment types such as money market funds and U.S. Treasury Bills and Notes.
Why It Matters
This filing provides investors with an update on Verve Therapeutics' financial position and operational segments for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a biotechnology company, Verve Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End (Covers financial data up to this date.)
- 2024-12-31 — Prior Year End (Provides a comparison point for financial performance.)
Key Players & Entities
- Verve Therapeutics, Inc. (company) — Filer of the 10-Q
- 201 Brookline Avenue, Suite 601, Boston, MA 02215 (address) — Business and Mail Address
- March 31, 2025 (date) — Reporting Period End Date
- December 31, 2024 (date) — Prior Year End Date
FAQ
What is Verve Therapeutics' primary business activity?
Verve Therapeutics, Inc. is involved in Pharmaceutical Preparations, as indicated by SIC code 2834.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 14, 2025.
What is the fiscal year end for Verve Therapeutics?
Verve Therapeutics' fiscal year ends on December 31.
What types of investments are mentioned in the filing?
The filing mentions investments in U.S. Agency Securities, Money Market Funds, and U.S. Treasury Bills and Notes.
What are the reported operating segments for the period?
The reported operating segments for the period January 1, 2025, to March 31, 2025, include 'Development'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Verve Therapeutics, Inc..